Cidara stock price target raised to $68 on strong flu prevention data

Guggenheim raised its price target on Cidara Therapeutics (NASDAQ:CDTX) to $68.00 from $50.00, maintaining a Buy rating, following impressive Phase 2b trial results for its flu prevention treatment, CD388. The trial demonstrated 76.1% protective efficacy at the 450mg dose with statistical significance (p<0.001), exceeding analyst expectations. Cidara management now plans to engage regulators for a potentially earlier Phase 3 start in the Northern Hemisphere this fall, shifting from a previously planned H1 2026 Southern Hemisphere launch, with Guggenheim citing "clear blockbuster potential" and additional upside from potential 2025 BARDA funding.

Analysis

Guggenheim has significantly upgraded its outlook on Cidara Therapeutics (NASDAQ:CDTX), raising its price target by 36% to $68.00 from $50.00 while maintaining a Buy rating. This revision is directly attributable to impressive results from the NAVIGATE Phase 2b trial for the company's flu prevention treatment, CD388. The trial demonstrated a 76.1% protective efficacy at the 450mg dose, a result that was both statistically significant (p<0.001) and exceeded analyst expectations. The data further established a clear dose-response relationship, strengthening the clinical case for the drug. Consequently, management is now pursuing an accelerated development timeline, seeking regulatory approval to initiate Phase 3 trials in the Northern Hemisphere this fall, a substantial pull-forward from the original H1 2026 plan. Guggenheim's commentary points to "clear blockbuster potential" for CD388, with a potential 2025 decision on Biomedical Advanced Research and Development Authority (BARDA) funding representing an additional upside catalyst.

Key Decisions for Investors

• The strong clinical data and accelerated timeline provide a compelling rationale for a bullish stance, as Guggenheim's $68 price target suggests significant potential upside.
• Investors should monitor for news regarding Cidara's engagement with regulators, as an earlier-than-expected start to Phase 3 trials would be a major de-risking event and a key near-term catalyst.
• The potential for a BARDA funding decision in 2025 should be tracked closely, as it represents a significant, non-dilutive financing opportunity that could further validate the treatment's potential and positively impact the stock.